Stay updated on ARGX-113 Safety & Efficacy in Pemphigus Clinical Trial
Sign up to get notified when there's something new on the ARGX-113 Safety & Efficacy in Pemphigus Clinical Trial page.

Latest updates to the ARGX-113 Safety & Efficacy in Pemphigus Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe screenshots show no changes to essential study details. Any differences are minor visual layout adjustments rather than updates to core content.SummaryDifference0.4%

- Check20 days agoNo Change Detected
- Check42 days agoChange DetectedMajor update: new operating-status notice and a v3.2.0 version release, replacing the old v3.1.0.SummaryDifference4%

- Check49 days agoChange DetectedThe page has been updated to Revision: v3.1.0, replacing the previous v3.0.2.SummaryDifference0.1%

- Check63 days agoChange DetectedUpdated the page from revision v3.0.1 to v3.0.2 and removed the 'Back to Top' element. No substantive content changes were introduced.SummaryDifference0.2%

- Check70 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.2%

- Check77 days agoChange DetectedThe web page has updated its facility name and location to Afula, Israel, and added specific drug information for efgartigimod alfa, while removing previous location details and outdated genetic disease resources.SummaryDifference2%

Stay in the know with updates to ARGX-113 Safety & Efficacy in Pemphigus Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARGX-113 Safety & Efficacy in Pemphigus Clinical Trial page.